Acute Myeloid Leukemia, LYT-200 and Fast Track
PureTech Drug Gets FDA Fast-Track Designation for Leukemia
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid leukemia, as well as a separate fast-track designation for the treatment of recurrent/metastatic head and neck squamous cell carcinomas.
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...
AML: Acute myeloid leukemia; CLL: C-type lectin-like molecule; CXCR: CXC chemokine receptor; N/A: Not applicable; NF: Nuclear factor. Acute myeloid leukemia (AML) remains incurable for the ...
Hosted on MSN5h
How Is Leukemia Diagnosed?Medically reviewed by Doru Paul, MD Leukemia is a cancer of the blood-forming tissues that often develops in the bone marrow.
Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...
Venetoclax is under clinical development by AbbVie and currently in Phase II for Relapsed Acute Myeloid Leukemia.
With a projected Compound Annual Growth Rate (CAGR) of $% during the forecast period (2022-2028), the US AML market is well-positioned for substantial progression, underpinned by the convergence of ...
In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...
Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback